Ajay P Malgi, Int. J. Res. Pharm. Sci., 2020, 11(4), 5752-5762 ORIGINAL ARTICLE INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES Published by JK Welfare & Pharmascope Foundation Journal Home Page: www.pharmascope.org/ijrps Anticancer activity of ylang-ylang essential oil in Ehrlich Ascites Carcinoma cell-treated mice Ajay P Malgi *1 , Vijaykumar P Rasal 1 , Vishal Shivalingappa Patil 2 , Priyanka P Patil 1 , Shamanad P Mallapur 3 , Vrushabh B Hupparage 1 , Sathgowda A Patil 1 1 Department of Pharmacology and Toxicology, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Belagavi-590010 Karnataka, India 2 Department of Molecular Biology and Biotechnology, ICMR- National Institute of Traditional Medicine, Belagavi-590010 Karnataka, India 3 Department of Toxicology, RCC Laboratories India Pvt. Ltd. Hyderabad- 500078 India Article History: Received on: 20 Jun 2020 Revised on: 19 Jul 2020 Accepted on: 29 Jul 2020 Keywords: Ylang Ylang, Cananga odorata, Ehrlich ascites carcinoma, 5-Fluorouracil, Anticancer ABSTRACT Essential oils are secondary metabolites contains a complex mixture of ter- penes with a diverse array of chemical structures, play a crucial role in the management of complex diseases like cancer via synergistic and antagonism effect. Ylang Ylang essential oil (YYEO) extracted from the ϑlowers of Cananga odorata is renowned for its fragrance, contained more than 150 essential components within it, and utilized in various diseases and cosmetics. Tradi- tionally YYEO is being used as an aphrodisiac, anxiolytics, antihypertensive, antiseptic, in food and beverages as a fragrance agent. Due to the presence of a complex mixture of essential components in YYEO, we aimed the cur- rent study to assess the anticancer potential against Ehrlich Ascites Carcinoma (EAC) bearing mice. In vitro antioxidant, tumour growth, body weight, bio- chemical, haematological, and serum estimation was evaluated with subse- quent histopathology of the liver. 5- Fluorouracil (5- FU) was used as a stan- dard drug. YYEO showed potent antioxidant activity by DPPH assay. YYEO signiϑicantly reversed the Hb, lymphocytes, WBC, and RBC numbers in the treated group compared with the disease control group. YYEO administration has restored the imbalanced levels of antioxidant biomarkers such as MDA, GSH, and SOD activity. YYEO reversed the histopathology of the liver altered by the EAC in mice. In conclusion, a complex mixture of terpenes contained in YYEO could be the potent anticancer therapy in the future. Further studies are needed to identify the active principles and the mechanism involved in this anti-tumour activity. * Corresponding Author Name: Ajay P Malgi Phone: 9686564635 Email: ajaymalgi@gmail.com ISSN: 0975-7538 DOI: https://doi.org/10.26452/ijrps.v11i4.3221 Production and Hosted by Pharmascope.org © 2020 | All rights reserved. INTRODUCTION Cancer is one of the leading cause of the mortal- ity worldwide responsible for an estimated 9.6 mil- lion deaths. In 2018 WHO reported that deaths due to cancer worldwide are continued to rise to over 11 million by 2030 (Bray et al., 2018). Can- cer develops in the cells that contain unrepaired damaged DNA which grow, divide and abnormally invade other parts of the body, instead of self- destruction through programmed cell death (Hana- han and Weinberg, 2011). To date, the manage- ment of this condition has been limited to the 5752 © International Journal of Research in Pharmaceutical Sciences